ascopubs.org

Gene-expression-profiling plus integrated multidisciplinary approach to detect new-generation risk-adapted prognostic index in smoldering myeloma and multiple myeloma (GIMPI).

The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Pharmaceutical Technology

Pharmaceutical Technology Excellence Awards 2025: BostonGene

BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...

New Data from SkylineDx Demonstrates Merlin CP-GEP Test's Superior Melanoma Risk Stratification

New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...
ascopubs.org

Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC).

Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

BostonGene to Present Seven Studies Unveiling Novel AI-Driven Breast Cancer Breakthroughs at SABCS 2025

Presentations showcase the power of omnimodal profiling to identify predictive immune signatures, comprehensively profile the tumor microenvironment and reveal novel therapeutic targets for optimized ...

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

DecisionDx-Melanoma demonstrates robust clinical utility and validated performance, supported by high-quality (SORT A) evidence showing accurate and consistent prognostic information for patients with ...